Louis Garguilo's Articles

  1. What If The Trump Tariff Strategy Works? 4/8/2025

    Doom and gloom in the drug development and manufacturing supply chain.  Predictions of disruptions and displacements. The Trump tariff ploy will fail, and costs/prices will skyrocket. But have you considered this “risk”? The tariff tantrum lowers national export/import duties for the entire globe.

  2. What Biotechs Learn From Takeda's Internal Manufacturing Competition 4/7/2025

    Biotechs can learn about outsourcing facility selection from a pharma company like Takeda, who evaluates both internal and external locations to place its development and manufacturing projects. This is part two of Chief Editor Louis Garguilo's discussion with Takeda Linz's Roland Fabris.

  3. Takeda's Award-Winning Facility Teaches You About Outsourcing 4/3/2025

    A Takeda production site in Linz, Austria, received an ISPE’s 2024 Facility of The Year Award. What’s so special about that location? The explanation from Roland Fabris, Site Head, will actually help you benchmark your CDMO, and demonstrate much about facility selection applicable to your own outsourcing needs. 

  4. Pain And Pleasure In Project Management Of CDMOs 3/17/2025

    Tony Sampognaro of Stoke Therapeutics, says, “We're having to rearrange and bolster the constellation of CDMOs we're working with." The nice thing is, Stoke has a comprehensive extended enterprise model. Nonetheless, an all-outsourced model “can add hidden complexity." Here's how to manage that.

  5. 'Fractional Hiring' At Your CDMO. Okay With You? 3/14/2025

    We need a flexible hiring marketplace – a new ecosystem – to generate increased awareness by professionals and students of positions in the biopharma industry. “It’s no longer about simply posting full-time jobs,” says Chris Frew, Founder/CEO of BioBuzz Networks. But is "fractional hiring" the answer?

  6. Talent Logistics Turns Biotech Winter To Hiring Spring 3/3/2025

    After our "Biotech Winter" – a period starting circa 2021 with tens of thousands of layoffs and stagnating investment — is it springtime for biotech? Chris Frew, Founder/CEO of BioBuzz Networks, says yes. “We have demonstrably entered a turning point in biotech hiring.”

  7. How Do We Categorize CDMOs? 2/24/2025

    Are we on the same page? Do we need to be? That is, how do we differ on what might seem like the mundane defining of CDMOs as small, medium, or large? Some readers have been asking. How might this determination be relative and important to individual sponsors? Our Advisory Board members weigh in.

  8. CDMOs Bet Big On Asia Expansion. Can Trump Reverse The Tide? 2/20/2025

    Facility investments by CDMOs continue to be magnetized to Asia. Recent examples abound. Chief Editor Louis Garguilo details some of those, and discusses whether, for example, a President Trump-intensified focus on increasing manufacturing in the U.S. can change this. Will your outsourcing in 2025 change direction? The answer may surprise you.

  9. Stop Hiring Now! Stay Virtual 2/17/2025

    Robert Discordia, Co-Founder, President and CEO, EQUULUS Therapeutics, knows that to advance early-stage development assets most economically, biotechs should (a) stay within their virtual model, and (b) base that outsourcing strategy on initial business objectives. Here are his dos and don'ts.

  10. They Said What? Unexpected Insights Into CDMO Selection 2/10/2025

    An assortment of conversations with experienced biopharma executives have generated some surprising commentary about CDMO selection. Chief Editor Louis Garguilo puts those insights together in this editorial. They include selection preparation/responsibilities, and some interesting CDMO behaviors of late.